AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
+5.44%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$180M
AUM Growth
+$180M
(+24%)
Cap. Flow
+$31.5M
Cap. Flow
% of AUM
17.49%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
287
New
77
Increased
46
Reduced
73
Closed
55
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$4.18M |
| 2 |
Invesco S&P 500 Pure Value ETF
RPV
|
$2.42M |
| 3 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$2.38M |
| 4 |
iShares Russell 1000 Value ETF
IWD
|
$2.37M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$2.17M |
Top Sells
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
$4.07M |
| 2 |
Invesco QQQ Trust
QQQ
|
$2.81M |
| 3 |
Invesco NASDAQ 100 ETF
QQQM
|
$2.81M |
| 4 |
Innoviva
INVA
|
$2.07M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$1.63M |
Sector Composition
| 1 | Healthcare | 59.95% |
| 2 | Real Estate | 10.67% |
| 3 | Financials | 4.01% |
| 4 | Technology | 3.11% |
| 5 | Consumer Discretionary | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Jazz Pharmaceuticals
JAZZ
$7.75B
| $5.05M | 2.8% |
40,750
+33,750
| +482% | +$4.18M |
|
2
Rithm Capital
RITM
$6.57B
| $4.6M | 2.55% |
491,699
| – | – |
|
3
Harmony Biosciences
HRMY
$2.12B
| $4.15M | 2.3% |
118,000
+50,500
| +75% | +$1.78M |
|
4
Galapagos
GLPG
$2.07B
| $4.03M | 2.23% |
99,000
+7,000
| +8% | +$285K |
|
5
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.01M | 2.23% |
570,000
+150,500
| +36% | +$1.06M |
|
|
6
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $3.9M | 2.16% |
912,500
+558,000
| +157% | +$2.38M |
|
7
Neurocrine Biosciences
NBIX
$13.8B
| $3.44M | 1.91% |
36,500
+21,000
| +135% | +$1.98M |
|
8
AdaptHealth
AHCO
$1.28B
| $3.44M | 1.91% |
282,500
+166,000
| +142% | +$2.02M |
|
|
EFC
9
Ellington Financial
EFC
$1.36B
| $3.3M | 1.83% |
239,271
+39,100
| +20% | +$540K |
|
10
Elanco Animal Health
ELAN
$9.12B
| $2.97M | 1.65% |
295,000
+80,000
| +37% | +$805K |
|
11
Arcutis Biotherapeutics
ARQT
$1.86B
| $2.79M | 1.55% |
292,500
+102,500
| +54% | +$977K |
|
12
Centene
CNC
$14.3B
| $2.7M | 1.5% |
40,000
-10,000
| -20% | -$675K |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.62M | 1.46% |
25,500
| – | – |
|
|
14
Invesco S&P 500 Pure Value ETF
RPV
$1.36B
| $2.42M | 1.34% |
+31,211
| New | +$2.42M |
|
|
15
iShares Russell 1000 Value ETF
IWD
$63.5B
| $2.37M | 1.31% |
+15,005
| New | +$2.37M |
|
|
16
Amylyx Pharmaceuticals
AMLX
$836M
| $2.33M | 1.29% |
108,000
+100,500
| +1,340% | +$2.17M |
|
|
WBA
17
DELISTED
Walgreens Boots Alliance
WBA
| $2.28M | 1.26% |
80,000
+52,000
| +186% | +$1.48M |
|
18
Pacira BioSciences
PCRX
$1.2B
| $2.26M | 1.26% |
56,500
+20,500
| +57% | +$821K |
|
|
19
iShares 1-3 Year Treasury Bond ETF
SHY
$24.5B
| $2.17M | 1.21% |
26,793
-50,199
| -65% | -$4.07M |
|
|
MFA
20
MFA Financial
MFA
$1.05B
| $2.11M | 1.17% |
187,725
+14,300
| +8% | +$161K |
|
21
Mr. Cooper
COOP
$12.1B
| $2.09M | 1.16% |
41,290
-15,500
| -27% | -$785K |
|
22
iShares MBS ETF
MBB
$41B
| $2.05M | 1.14% |
+21,955
| New | +$2.05M |
|
23
Embecta
EMBC
$847M
| $2.02M | 1.12% |
+93,500
| New | +$2.02M |
|
24
Insmed
INSM
$28.8B
| $2M | 1.11% |
95,000
+10,500
| +12% | +$222K |
|
25
United Therapeutics
UTHR
$13.8B
| $1.99M | 1.1% |
9,000
+5,500
| +157% | +$1.21M |
|